DLB · XBRL financial data
Dolby Laboratories financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (DLB's year ends in late September)
| In millions of dollars | Sep 29, 2023 | Dec 29, 2023 | Mar 29, 2024 | Jun 28, 2024 | Sep 27, 2024 | Dec 27, 2024 | Mar 28, 2025 | Jun 27, 2025 | Sep 26, 2025 | Dec 26, 2025 | Mar 27, 2026 | Jun 26, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 316 | 365 | 289 | — | 357 | 370 | 316 | — | 347 | 396 | 305 |
| Revenue from contracts with customers | 291* | 316 | 365 | 289 | 305* | 357 | 370 | 316 | 307* | 347 | 396 | 305 |
| Cost of revenue | 36* | 32 | 39 | 36 | 34* | 41 | 36 | 44 | 40* | 43 | 45 | 40 |
| Gross profit | 255* | 284 | 326 | 253 | 271* | 316 | 334 | 272 | 268* | 303 | 351 | 265 |
| Research and development | 70* | 67 | 62 | 66 | 69* | 67 | 62 | 66 | 67* | 69 | 64 | 66 |
| General and administrative | 67* | 65 | 67 | 69 | 69* | 70 | 70 | 72 | 74* | 70 | 76 | 76 |
| Total operating expenses | 259* | 217 | 217 | 216 | 224* | 236 | 226 | 224 | 238* | 241 | 238 | 230 |
| Operating income (loss) | (3)* | 66 | 109 | 37 | 46* | 80 | 108 | 48 | 30* | 62 | 113 | 34 |
| Interest income | — | 9 | 9 | 9 | — | 3 | 4 | 4 | — | 4 | 5 | 3 |
| Other income (expense) | 3* | 5 | 4 | 4 | 7* | 4 | 9 | 4 | 7* | 5 | 2 | 6 |
| Income tax expense (benefit) | (1)* | 13 | 24 | 11 | 1* | 18 | 28 | 9 | (8)* | 18 | 24 | 15 |
| Net income (loss) | 9* | 67 | 98 | 38 | 59* | 68 | 92 | 46 | 49* | 53 | 95 | 29 |
| Earnings per share, basic USD per share | 0.10* | 0.70 | 1.02 | 0.40 | 0.61* | 0.71 | 0.95 | 0.48 | 0.52* | 0.56 | 1.00 | 0.30 |
| Earnings per share, diluted USD per share | 0.09* | 0.69 | 1.01 | 0.40 | 0.60* | 0.70 | 0.94 | 0.48 | 0.50* | 0.55 | 0.99 | 0.30 |
| Weighted average shares, basic millions of shares | 96* | 95 | 96 | 96 | 95* | 96 | 96 | 96 | 96* | 95 | 95 | 94 |
| Weighted average shares, diluted millions of shares | 99* | 97 | 97 | 97 | 98* | 97 | 97 | 97 | 98* | 97 | 96 | 95 |
Balance sheet
CSVFiscal quarters (DLB's year ends in late September)
Cash flows
CSVFiscal quarters (DLB's year ends in late September)
| In millions of dollars | Sep 29, 2023 | Dec 29, 2023 | Mar 29, 2024 | Jun 28, 2024 | Sep 27, 2024 | Dec 27, 2024 | Mar 28, 2025 | Jun 27, 2025 | Sep 26, 2025 | Dec 26, 2025 | Mar 27, 2026 | Jun 26, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | 9* | 67 | 98 | 38 | 59* | 68 | 92 | 46 | 49* | 53 | 95 | 29 |
| Stock-based compensation | 28* | 32 | 29* | 29* | 30* | 36 | 31* | 31* | 31* | 37 | 31* | 31* |
| Net cash from operating activities | 85* | 8 | 181* | 21* | 116* | 107 | 175* | 68* | 123* | 55 | 93* | 167* |
| Purchases of property and equipment | 8* | 6 | 9* | 8* | 7* | 7 | 7* | 6* | 16* | 5 | 9* | 15* |
| Net cash from investing activities | (20)* | 1 | (18)* | (8)* | (261)* | (8) | 26* | (6)* | (22)* | 1 | (46)* | (10)* |
| Share repurchases | 25 | 80 | 25 | 35 | 20 | 15 | 35 | 40 | 35 | 70 | 65 | 65 |
| Dividends paid | 26* | 29 | 29* | 29* | 29* | 32 | 32* | 32* | 32* | 34 | 34* | 34* |
| Net cash from financing activities | (43)* | (125) | (44)* | (58)* | (60)* | (58) | (65)* | (61)* | (64)* | (122) | (100)* | (91)* |
| Net change in cash | 19* | (109) | 116* | (46)* | (201)* | 34 | 139* | 6* | 37* | (66) | (54)* | 65* |
Compare with peers
SIC 6794 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 6794 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| Dolby Laboratories | 669 | 305 | 167* | not reported | 10-QJun 26, 2026 |
| Broadstone Net Lease | 12 | 122 | 88* | 192.0M | 10-QSep 30, 2026 |
| Potlatchdeltic | 89 | 314 | 66* | 77.3M | 10-QSep 30, 2025 |
| Lineage | 58 | 1,361 | 311* | 227.7M | 10-QJun 30, 2026 |
| National Health Investors | 30 | 121 | 65* | 49.1M | 10-QJun 30, 2026 |
| Blackstone Mortgage Trust | 512 | not reported | (18)* | 166.0M | 10-QSep 30, 2026 |
| HA Sustainable Infrastructure Capital | 250 | 121 | 68* | 128.5M | 10-QJun 30, 2026 |
| Highwoods Properties | 279 | 218 | not reported | 110.3M | 10-QSep 30, 2026 |
| Four Corners Property Trust | 7.2 | 8 | 61* | 109.8M | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.